Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 16/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.57 |
| ▸ | CYP2E1 | P05181 | 7/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 7/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12195715 | 0.86 | CYP2A6 (0.57) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2E1 | |
| SCHEMBL1425328 | 0.83 | CYP2A6 (0.54) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2E1 | |
| SCHEMBL5795505 | 0.78 | PDGFRB (0.48) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2E1 | |
| SCHEMBL15695315 | 0.78 | KDM4E (0.47) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2E1 | |
| SCHEMBL6741567 | 0.77 | CYP2A6 (0.59) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2E1 | |
| SCHEMBL18390779 | 0.77 | HSD17B1 (0.61) | HSD17B1HSD17B2ALDH1A1ESR1ESR2 | |
| SCHEMBL17060254 | 0.76 | CYP2A6 (0.43) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2E1 | |
| SCHEMBL364131 | 0.76 | GPR35 (0.56) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2E1 | |
| SCHEMBL10205948 | 0.75 | ESR1 (0.66) | HSD17B1HSD17B2ALDH1A1ESR1ESR2 | |
| SCHEMBL9670331 | 0.75 | ALOX5 (0.51) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307410-B2 | Mcl-1 modulating compounds for cancer treatment | CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2019-06-04 | — | — | US | disclosed |
| EP-3114119-B1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | CENTRE DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2019-05-01 | — | — | EP | disclosed |
| US-20170071921-A1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2017-03-16 | — | — | US | disclosed |
| EP-3114119-A1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | Centre de Lutte Contre le Cancer Francois Baclesse (FR) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015132727-A1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2015-09-11 | — | — | WO | disclosed |
| EP-2915811-A1 | MCL-1 modulating compounds for cancer treatment | Centre Régional de Lutte contre le Cancer - Centre François Baclesse (FR) | 2015-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071921-A1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | MCL1, BCL2A1, BCL2L1 | CYP2A6 3028/4885CYP3A4 3877/4885CYP2C9 4203/4885 |
| US-10307410-B2 | Mcl-1 modulating compounds for cancer treatment | MCL1, BCL2A1, BCL2L1 | CYP2A6 3028/4885CYP3A4 3877/4885CYP2C9 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.